Hydrafinil

Hydrafinil (9-fluorenol) is a eugeroic — a wakefulness-promoting agent — built on the fluorene scaffold rather than the diphenylmethylsulfinyl chemistry of modafinil. Its pharmacology is incompletely characterized: the entire first-party dataset comes from a single Cephalon-led SAR series that identified fluoren-9-ol as the active wake-promoting metabolite of a broader screen. What follows is what the literature actually supports, separated cleanly from the vendor mythology.

Weak Dopamine Transporter Inhibition#

The only formally measured receptor-level interaction is at the dopamine transporter (DAT), where fluorenol binds with low micromolar affinity.

"Fluorenol binds the dopamine transporter with an IC₅₀ of approximately 9 μM, a much lower affinity than modafinil, and its potential mechanism of action remains incompletely explained in available literature." — Wikipedia contributors, Wikipedia (2024)

This is meaningful for two reasons. First, the affinity is genuinely weak — roughly an order of magnitude below modafinil's — which means DAT blockade alone cannot explain the wake signal. Second, the milder dopaminergic footprint is the mechanistic basis for the cleaner subjective profile users report compared to amphetamine-class stimulants: less euphoria, less reinforcement, less jaw-clench, less crash. The trade-off is that the compound also lacks the harder edge that some users want from modafinil for marathon work sessions.

DAT-Independent Wakefulness#

Despite weaker DAT binding, fluorenol outperformed modafinil on EEG/EMG-measured wakefulness in rats over a 4-hour post-dose window in the original Cephalon work.

"Fluorenol exhibited a more potent wake-promoting effect than modafinil for 4 h postadministration as measured by EEG/EMG in rats, despite its weaker affinity for the dopamine transporter." — Jeon HY et al., Bioorganic & Medicinal Chemistry Letters (2012)

The implication is that DAT is along for the ride, not driving. The same conclusion has been reached for modafinil itself in the broader pharmacology literature:

"The wake-promoting effects of modafinil do not depend solely on inhibition of dopamine reuptake but also involve other neurotransmitter systems." — Mereu M et al., Psychopharmacology (2013)

The working model — extrapolated from the broader eugeroic class rather than directly demonstrated for fluorenol — invokes increased histaminergic tone via the tuberomammillary nucleus, orexin/hypocretin activation, and downstream cortical norepinephrine and glutamate release. None of this has been directly measured for fluorenol. Practically, this is why the subjective effect feels less like a stimulant and more like the suppression of sleep pressure: cognition stays clean, attention sharpens, but the racing-heart, twitchy quality of amphetamines is absent.

Short Duration of Action#

The wake signal in the Cephalon rat work resolved within ~4 hours, and community pharmacokinetic estimates put the subjective duration in humans at roughly 4–6 hours — versus the 12–15 hour half-life of modafinil.

"Modafinil's pharmacokinetic profile is characterized by rapid absorption and a mean half-life of 12–15 hours; this serves as a clinical point of comparison when evaluating the effects and window of related eugeroics." — Kim D, Environmental Health and Toxicology (2012)

This is the single most important practical feature of the compound. The short window is precisely what makes hydrafinil attractive for physique-focused users running a cut, where modafinil's long tail wrecks sleep onset and blunts the GH pulse. A morning dose clears before the evening cortisol/melatonin transition, preserving sleep architecture — which is non-negotiable for anyone serious about recovery, appetite control, and body composition.

Clean Cytochrome Profile#

Modafinil is a notorious CYP3A4 inducer and CYP2C19 inhibitor — the reason it interacts with hormonal contraceptives, SSRIs, and a long list of other substrates. Fluorenol appears to dodge at least part of that liability.

"Unlike modafinil, fluorenol demonstrated no significant affinity for CYP2C19 in vitro, suggesting an improved drug-drug interaction profile." — Jeon HY et al., Bioorganic & Medicinal Chemistry Letters (2012)

For users layering hydrafinil into stacks that already include SSRIs, finasteride, tadalafil, or hormonal compounds metabolized through the CYP system, this is mechanistically reassuring — though "no affinity in vitro" is not the same as "no clinically meaningful interaction." Formal human DDI studies do not exist. The conservative read is that the interaction surface is narrower than modafinil's, not zero.

What the Literature Does Not Support#

Two mechanisms circulate on vendor pages and should be flagged:

• "5-HT₆ antagonism" — no published binding data exists for fluorenol at any serotonin receptor. This claim originates from marketing copy, not pharmacology.
• "Modafinil analog" / "modafinil metabolite" — fluorenol is not a metabolite of modafinil and shares no structural class with it beyond both being non-amphetamine eugeroics. The shared label is functional, not chemical.

Treating these as mechanistic facts inflates expectations. The honest summary: hydrafinil is a weak DAT inhibitor with a stronger-than-DAT-predicted wake signal, a short duration, and a probably cleaner CYP footprint than modafinil — and the rest of the receptor map remains genuinely unmapped.

Common (most users)#

• Headache — the single most-reported effect, dose-dependent above ~75mg. Most users find it resolves with adequate hydration and 300–600mg alpha-GPC or CDP-choline co-administered with the dose. If headache persists at 100mg, the protocol is to drop to 50–75mg rather than stack more choline.
• Mild jitter / restlessness — particularly when stacked with caffeine. 200mg L-theanine smooths the edge without blunting the wake signal. Lowering caffeine before raising hydrafinil is the cleaner adjustment.
• Dry mouth — minor and transient. Standard hydration.
• Mild GI upset — usually first-dose only. Administering with food resolves it in most users.
• Sleep latency push — only an issue when dosed past late morning. The short ~5h subjective window assumes an AM dose; any dose after ~12pm risks pushing sleep onset past 30 minutes.
• Rapid tolerance — not a side effect per se but the most common reason users feel the compound "stopped working." Dosing 2–4 days per week, not daily, is the documented mitigation. Cross-tolerance with modafinil/armodafinil is partial but real.

Uncommon (dose-dependent or individual)#

• Resting heart rate elevation (5–10 bpm) — dose-dependent, more common at 150mg+ and in stimulant-stacked protocols. RHR is the cheapest at-home marker; if it drifts up persistently on dosing days, the protocol calls for backing down to 50–75mg or dropping caffeine from the stack.
• Mild blood pressure elevation — same pattern as RHR. Worth a cuff check at week 1 and week 3 in any protocol running 100mg+.
• Anxiety / overstimulation — reported at 150mg and above, and in users sensitive to dopaminergic agents. Drop dose rather than add anxiolytics.
• Non-linear dose response above 150mg — community reports consistently describe diminishing or paradoxically worse effects above 150mg (r/Nootropics dose-response thread). More is not better; this is a plateau compound.
• Bruxism / jaw tension — rare and notably milder than on modafinil, but possible at higher doses or in stacks.
• Appetite suppression — useful on a cut, but worth tracking on aggressive deficits where protein intake is already at the floor.

Rare but serious#

• Tachycardia / palpitations — uncommon at protocol doses but the relevant warning sign for anyone with subclinical cardiac issues. Stop immediately if sustained palpitations appear.
• Acute hypertensive episode — possible in users with undiagnosed hypertension or when stacked with multiple sympathomimetics. The signal is headache that doesn't respond to hydration plus a measurably elevated cuff reading.
• Severe insomnia / multi-day sleep disruption — almost always from afternoon dosing or stacking with long-half-life stimulants. Discontinue and reset before re-initiating.
• Hypersensitivity reactions — rash, swelling, or respiratory symptoms. Vanishingly rare in community reports but the standard "stop and don't re-challenge" rule applies.

A note on the evidence ceiling: there is no published long-term mammalian safety dataset for fluorenol. Carcinogenicity and chronic toxicity are formally uncharacterized.

"Fluorenol exhibited a more potent wake-promoting effect than modafinil for 4 h postadministration as measured by EEG/EMG in rats, despite its weaker affinity for the dopamine transporter." — Jeon HY et al., Bioorg Med Chem Lett (2012)

The wake signal is real; the toxicology file behind it is thin. Conservative dosing and intermittent scheduling are the rational response to that asymmetry.

Hard contraindications#

• Uncontrolled hypertension — do not initiate. Manage BP first.
• Structural heart disease, arrhythmias, or known cardiovascular disease — avoid. Standard eugeroic/sympathomimetic contraindication.
• MAOI co-administration — avoid on mechanistic grounds. No formal interaction studies exist, but the catecholaminergic profile makes co-administration unjustifiable.
• Pregnancy and lactation — no data, formally contraindicated.
• Afternoon or evening dosing — non-negotiable for anyone serious about recovery. The entire point of choosing hydrafinil over modafinil is the shorter window; surrendering sleep defeats the selection.
• Stacking with amphetamines, methylphenidate, high-dose yohimbine, or other potent sympathomimetics — additive cardiovascular load with no published interaction data. Caffeine at moderate doses (100–200mg) is the upper edge of sensible stimulant stacking.

Gender, hormonal, and PCT considerations#

Hydrafinil is non-hormonal. It does not bind androgen, estrogen, or progesterone receptors, does not aromatize, and does not affect the HPTA. No PCT is required and the compound can be run independently of any AAS or SARM cycle without interaction concerns at the endocrine level.

Dosing windows apply uniformly across subjects. Lower-bodyweight users — typically female users — generally titrate from the bottom of the beginner range (25mg) rather than scaling by bodyweight per se; the dose-response is non-linear enough that starting low is the correct approach regardless of mass.

One CYP note worth flagging as a positive: unlike modafinil, fluorenol shows no meaningful affinity for CYP2C19 in vitro, which is the mechanistic basis for the community observation that it does not interact with hormonal contraceptives the way modafinil does.

"Unlike modafinil, fluorenol demonstrated no significant affinity for CYP2C19 in vitro, suggesting an improved drug-drug interaction profile." — Jeon HY et al., Bioorg Med Chem Lett (2012)

This is an in-vitro inference, not a clinical guarantee — but it is the cleanest distinguishing feature on the safety side versus the parent eugeroic class.